Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009181 | 0.86 | PER2 (0.32) | PER2CRY2 | |
| SCHEMBL20009180 | 0.77 | CYP3A4 (0.32) | CYP3A4PER2CRY2 | |
| SCHEMBL29312341 | 0.67 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL14218297 | 0.65 | LMNA (0.37) | — | |
| SCHEMBL24909957 | 0.64 | FKBP1A (0.39) | GBA1MAPT | |
| SCHEMBL12251961 | 0.64 | APEX1 (0.55) | GBA1 | |
| SCHEMBL12252004 | 0.64 | FKBP1A (0.39) | GBA1MAPT | |
| SCHEMBL179075 | 0.62 | GAA (0.34) | PER2 | |
| SCHEMBL29348317 | 0.62 | PER2 (0.34) | PER2 | |
| SCHEMBL9068590 | 0.62 | L3MBTL1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | GBA1 39/4885CYP3A4 786/4885MAPT 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.